1. Australian Bureau of Statistics. Health conditions prevalence: key findings on selected long-term conditions and prevalence in Australia [Internet]. Canberra: Australian Bureau of Statistics; 2022 [cited 2022 Nov 1]. Available from: https://www.abs.gov.au/statistics/health/health-conditions-and-risks/health-conditions-prevalence/latest-release

2. Firouzabadi FD, Shab-Bidar S, Jayedi A. The effects of omega-3 polyunsaturated fatty acids supplementation in pregnancy, lactation, and infancy: an umbrella review of meta-analyses of randomized trials. Pharmacol Res. 2022 Mar;177:106100. DOI: 10.1016/j.phrs.2022.106100

3. Rytter D, Christensen JH, Bech BH, Schmidt EB, Henriksen TB, Olsen SF. The effect of maternal fish oil supplementation during the last trimester of pregnancy on blood pressure, heart rate and heart rate variability in the 19-year-old offspring. Br J Nutr. 2012 Oct;108(8):1475-83. doi: 10.1017/S0007114511006799.

4. Campoy C, Escolano-Margarit MV, Ramos R, Parrilla-Roure M, Csábi G, Beyer J, et al. Effects of prenatal fish-oil and 5-methyltetrahydrofolate supplementation on cognitive development of children at 6.5 y of age. Am J Clin Nutr. 2011 Dec;94(6 Suppl):1880S-8S. doi: 10.3945/ajcn.110.001107.

5. Nevins JEH, Donovan SM, Snetselaar L, Dewey KG, Novotny R, Stang J, et al. Omega-3 fatty acid dietary supplements consumed during pregnancy and lactation and child neurodevelopment: a systematic review. J Nutr. 2021 Nov;151(11):3483-3494. DOI: 10.1093/jn/nxab238

6. Mozurkewich EL, Greenwood M, Clinton C, Berman D, Romero V, Djuric Z, et al. Pathway markers for pro-resolving lipid mediators in maternal and umbilical cord blood: a secondary analysis of the mothers, omega-3, and mental health study. Front Pharmacol. 2016 Sep;7:274. doi: 10.3389/fphar.2016.00274.

7. Elliott E, Hanson CK, Anderson-Berry AL, Nordgren TM. The role of specialized pro-resolving mediators in maternal-fetal health. Prostaglandins Leukot Essent Fatty Acids. 2017 Nov;126:98-104. doi: 10.1016/j.plefa.2017.09.017.

8.   Wu S, Zhu C, Wang Z, Wang S, Yuan P, Song T, et al. Effects of fish oil supplementation on cardiometabolic risk factors in overweight or obese children and adolescents: a meta-analysis of randomized controlled trials. Front Pediatr. 2021 Apr 27;9. doi: 10.3389/fped.2021.604469.

9. D'Vaz N, Meldrum SJ, Dunstan JA, Lee-Pullen TF, Metcalfe J, Holt BJ, et al. Fish oil supplementation in early infancy modulates developing infant immune responses. Clin Exp Allergy. 2012 Aug;42(8):1206-1216. DOI: 10.1111/j.1365-2222.2012.04031.x

10. Robertsen I, Åsberg A, Jenssen TG, Gence B, Tore Vethe N, Midtvedt K, et al. Increased systemic exposure of once-daily tacrolimus in renal transplant recipients on marine omega-3 fatty acid supplementation. Transpl Int. 2021 Jul;34(7):1322-1324. DOI: 10.1111/tri.13917

11. Cortinovis M, Gotti E, Remuzzi G, Perico N, Cattaneo D, Baldelli S. Omega-3 polyunsaturated fatty acids affect sirolimus exposure in kidney transplant recipients on calcineurin inhibitor-free regimen. Transplantation. 2010 Jan;15;89(1):126-127. DOI: 10.1097/TP.0b013e3181c280df

12. Busnach G, Stragliotto E, Minetti E, Perego A, Brando B, Broggi ML, et al. Effect of n-3 polyunsaturated fatty acids on cyclosporine pharmacokinetics in kidney graft recipients: a randomized placebo-controlled study. J Nephrol. 1998;11(2):87-93.

13. Dalli J, Gomez EA, Jouvene CC. Utility of the specialized pro-resolving mediators as diagnostic and prognostic biomarkers in disease. Biomolecules. 2022 Feb;12(3):353. DOI: 10.3390/biom12030353

14. Dyall SC, Balas L, Bazan NG, Brenna JT, Chiang N, Da Costa Souza F, et al. Polyunsaturated fatty acids and fatty acid-derived lipid mediators: recent advances in the understanding of their biosynthesis, structures, and functions. Prog Lipid Res. 2022 Apr;86:101165. DOI: 10.1016/j.plipres.2022.101165

15. Basil MC, Levy BD. Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. Nat Rev Immunol. 2016 Jan;16(1):51-67. DOI: 10.1038/nri.2015.4

16. Serhan CN. Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms. FASEB J. 2017 Apr;31(4):1273-1288. DOI: 10.1096/fj.201601222R

17. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014 Jun;510(7503):92-101. DOI: 10.1038/nature13479

18. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res. 2010 Nov;107(10):1170-1184. DOI: 10.1161/CIRCRESAHA.110.223883

19. Chiang N, Serhan CN. Specialized pro-resolving mediator network: an update on production and actions. Essays Biochem. 2020 Sep;64(3):443-462. DOI: 10.1042/EBC20200018

20. Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest. 2018 Jul;128(7):2657-2669. DOI: 10.1172/JCI97943

21. Fullerton JN, O'Brien AJ, Gilroy DW. Lipid mediators in immune dysfunction after severe inflammation. Trends Immunol. 2014 Jan;35(1):12-21. DOI: 10.1016/j.it.2013.10.008

22. Vong L, Ferraz JGP, Dufton N, Panaccione R, Beck PL, Sherman PM, et al. Up-regulation of annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis. PLoS One. 2012;7(6):e39244. DOI: 10.1371/journal.pone.0039244

23. Kooij G, Troletti CD, Leuti A, Norris PC, Riley I, Albanese M, et al. Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction. Haematologica. 2020 Aug;105(8):2056-2070. DOI: 10.3324/haematol.2019.219519

24. Navarini L, Bisogno T, Margiotta DPE, Piccoli A, Angeletti S, Laudisio A, et al. Role of the specialized proresolving mediator resolvin D1 in systemic lupus erythematosus: preliminary results. J Immunol Res. 2018;2018:5264195. DOI: 10.1155/2018/5264195

25. Chen S, Wu RF, Su L, Zhou WD, Zhu MB, Chen QH. Lipoxin A4 regulates expression of the estrogen receptor and inhibits 17β-estradiol induced p38 mitogen-activated protein kinase phosphorylation in human endometriotic stromal cells. Fertil Steril. 2014 Jul;102(1):264-271. DOI: 10.1016/j.fertnstert.2014.03.029

26. Bosco A, Dessì A, Zanza C, Pintus R, Fanos V. Resolvins' obesity-driven deficiency: the implications for maternal-fetal health. Nutrients. 2022 Apr;14(8):1662. DOI: 10.3390/nu14081662

27. Miyata J, Fukunaga K, Iwamoto R, Isobe Y, Niimi K, Takamiya R, et al. Dysregulated synthesis of protectin D1 in eosinophils from patients with severe asthma. J Allergy Clin Immunol. 2013 Feb;131(2):353-60.e1-2. DOI: 10.1016/j.jaci.2012.07.048

28. Bozinovski S, Uddin M, Vlahos R, Thompson M, McQualter JL, Merritt AS, et al. Serum amyloid A opposes lipoxin A₄ to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A. 2012 Jan;109(3):935-940. DOI: 10.1073/pnas.1109382109

29. Wang X, Miao Z, Xu X, Schultzberg M, Zhao Y. Reduced levels of plasma lipoxin A4 are associated with post-stroke cognitive impairment. J Alzheimers Dis. 2021;79(2):607-613. DOI: 10.3233/JAD-201050

30. Cata JP, Velasquez JF, Ramirez MF, Vauthey JN, Gottumukkala V, Conrad C, et al. Inflammation and pro-resolution inflammation after hepatobiliary surgery. World J Surg Oncol. 2017 Aug;15(1):152. DOI: 10.1186/s12957-017-1220-6

31. Tao X, Lee MS, Donnelly CR, Ji RR. Neuromodulation, specialized proresolving mediators, and resolution of pain. Neurotherapeutics. 2020 Jul;17(3):886-899. DOI: 10.1007/s13311-020-00892-9

32. Fattori V, Zaninelli TH, Rasquel-Oliveira FS, Casagrande R, Verri WA. Specialized pro-resolving lipid mediators: a new class of non-immunosuppressive and non-opioid analgesic drugs. Pharmacol Res. 2020 Jan;151:104549. DOI: 10.1016/j.phrs.2019.104549

33. Han YH, Lee K, Saha A, Han J, Choi H, Noh M, et al. Specialized proresolving mediators for therapeutic interventions targeting metabolic and inflammatory disorders. Biomol Ther (Seoul). 2021 Sep;29(5):455-464. DOI: 10.4062/biomolther.2021.094

34. Fredman G, Spite M. Specialized pro-resolving mediators in cardiovascular diseases. Mol Aspects Med. 2017 Dec;58:65-71. DOI: 10.1016/j.mam.2017.02.003

35. Yang A, Wu Y, Yu G, Wang H. Role of specialized pro-resolving lipid mediators in pulmonary inflammation diseases: mechanisms and development. Respir Res. 2021 Jul;22(1):204. DOI: 10.1186/s12931-021-01792-y

36. Valente M, Dentoni M, Bellizzi F, Kuris F, Gigli GL. Specialized pro-resolving mediators in neuroinflammation: overview of studies and perspectives of clinical applications. Molecules. 2022 Jul;27(15):4836. DOI: 10.3390/molecules27154836

37. Zaninelli TH, Fattori V, Verri WA. Harnessing inflammation resolution in arthritis: current understanding of specialized pro-resolving lipid mediators' contribution to arthritis physiopathology and future perspectives. Front Physiol. 2021;12:729134. DOI: 10.3389/fphys.2021.729134

38. Lavy M, Gauttier V, Poirier N, Barillé-Nion S, Blanquart C. Specialized pro-resolving mediators mitigate cancer-related inflammation: role of tumor-associated macrophages and therapeutic opportunities. Front Immunol. 2021;12:702785. DOI: 10.3389/fimmu.2021.702785

39. Ontoria-Oviedo I, Amaro-Prellezo E, Castellano D, Venegas-Venegas E, González-Santos F, Ruiz-Saurí A, et al. Topical administration of a marine oil rich in pro-resolving lipid mediators accelerates wound healing in diabetic db/db mice through angiogenesis and macrophage polarization. Int J Mol Sci. 2022 Aug;23(17):9918. DOI: 10.3390/ijms23179918

40. Papathanasiou E, Scott AR, Trotman CA, Beale C, Price LL, Huggins GS, et al. Specialized pro-resolving mediators reduce scarring after cleft lip repair. Front Immunol. 2022;13:871200. DOI: 10.3389/fimmu.2022.871200

41. Wu SH, Chen XQ, Liu B, Wu HJ, Dong L. Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema. Br J Dermatol. 2013 Jan;168(1):172-178. DOI: 10.1111/j.1365-2133.2012.11177.x

42. Kumar V, Yasmeen N, Chaudhary AA, Alawam AS, Al-Zharani M, Suliman Basher N, et al. Specialized pro-resolving lipid mediators regulate inflammatory macrophages: a paradigm shift from antibiotics to immunotherapy for mitigating COVID-19 pandemic. Front Mol Biosci. 2023;10:1104577. DOI: 10.3389/fmolb.2023.1104577

43. Balta MG, Papathanasiou E, Christopoulos PF. Specialized pro-resolving mediators as potential regulators of inflammatory macrophage responses in COVID-19. Front Immunol. 2021;12:632238. DOI: 10.3389/fimmu.2021.632238

44. National Health and Medical Research Council. Nutrient reference values for Australia and New Zealand including recommended dietary intakes [Internet]. Canberra ACT: National Health and Medical Research Council; 2006 [cited 2022 Jun 9]. Available from: https://www.nhmrc.gov.au/sites/default/files/images/nutrient-refererence-dietary-intakes.pdf

45. Natural Medicines Database [Internet]. Denver (CO): TRC Healthcare; 2023. Eicosapentaenoic acid (EPA); 2023 Jun [cited 2023 Oct 17]. Available from: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=994

46. Government of Canada. Monograph: fish oil [Internet]. Ottawa: Government of Canada; 2018 [cited 2023 Nov 1]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=88

47. Natural Medicines Database [Internet]. Denver (CO): TRC Healthcare; 2023. Docosahexaenoic acid (DHA); 2023 Sep [cited 2023 Oct 17]. Available from: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=864

48. Richter CK, Skulas-Ray AC, Kris-Etherton PM. Recommended intake of fish and fish oils worldwide. In: Raatz SK, Bibus DM, editors. Fish and fish oil in health and disease prevention [Internet]. Cambridge: Academic Press; 2016 [cited 2023 Nov 1]. Chapter 3. Available from: https://www.sciencedirect.com/book/9780128028445/fish-and-fish-oil-in-health-and-disease-prevention

49. Callan N, Hanes D, Bradley R. Early evidence of efficacy for orally administered SPM-enriched marine lipid fraction on quality of life and pain in a sample of adults with chronic pain. J Transl Med. 2020 Oct;18(1):401. DOI: 10.1186/s12967-020-02569-5

50. Möller I, Rodas G, Villalón JM, Rodas JA, Angulo F, Martínez N, et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of treatment with an SPMs-enriched oil on chronic pain and inflammation, functionality, and quality of life in patients with symptomatic knee osteoarthritis: GAUDI study. J Transl Med. 2023 Jun;21(1):423. DOI: 10.1186/s12967-023-04283-4

51. Jaja-Chimedza A, Hirsh S, Bruce D, Bou-Sliman T, Joyal S, Swick AG. The effects of an SPM-enriched marine oil and bioavailable curcumin combination on inflammation-associated discomfort in generally healthy individuals: a virtual open-label pilot study. Transl Med Commun. 2022;7(25). DOI: 10.1186/s41231-022-00131-7

52. Schaller MS, Chen M, Colas RA, Sorrentino TA, Lazar AA, Grenon SM, et al. Treatment with a marine oil supplement alters lipid mediators and leukocyte phenotype in healthy patients and those with peripheral artery disease. J Am Heart Assoc. 2020 Aug;9(15):e016113. DOI: 10.1161/JAHA.120.016113

53. Al-Shaer AE, Regan J, Buddenbaum N, Tharwani S, Drawdy C, Behee M, et al. Enriched marine oil supplement increases specific plasma specialized pro-resolving mediators in adults with obesity. J Nutr. 2022 Jul;152(7):1783-1791. DOI: 10.1093/jn/nxac075

54. Souza PR, Marques RM, Gomez EA, Colas RA, De Matteis R, Zak A, et al. Enriched marine oil supplements increase peripheral blood specialized pro-resolving mediators concentrations and reprogram host immune responses: a randomized double-blind placebo-controlled study. Circ Res. 2020 Jan;126(1):75-90. DOI: 10.1161/CIRCRESAHA.119.315506